Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Improving outcomes for oestrogen receptor positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.06.17
Views: 7866

Dr Giancarlo Pruneri - European Institute of Oncology, Milan, Italy

Dr Pruneri talks to ecancer at IFCPE 2017 about treating the 20% of oestrogen-receptor positive breast cancer patients who relapse following first-line treatments.

He describes how comparative genotyping of primary tumours and subsequent lesions could reveal treatment resistance, giving the example of recent research exposing aromatase inhibitor resistance.

Dr Pruneri spoke further about aromatase gene amplification further here.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation